GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jasper Therapeutics Inc (NAS:JSPR) » Definitions » Market Cap

Jasper Therapeutics (Jasper Therapeutics) Market Cap : $369.90 Mil (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Jasper Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Jasper Therapeutics's share price for the quarter that ended in Mar. 2024 was $29.36. Jasper Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 15.09 Mil. Therefore, Jasper Therapeutics's market cap for the quarter that ended in Mar. 2024 was $442.91 Mil.

Jasper Therapeutics's quarterly market cap increased from Sep. 2023 ($77.60 Mil) to Dec. 2023 ($88.08 Mil) and increased from Dec. 2023 ($88.08 Mil) to Mar. 2024 ($442.91 Mil).

Jasper Therapeutics's annual market cap declined from Dec. 2021 ($297.16 Mil) to Dec. 2022 ($18.37 Mil) but then increased from Dec. 2022 ($18.37 Mil) to Dec. 2023 ($88.08 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Jasper Therapeutics's Enterprise Value for Today is $253.98 Mil.


Jasper Therapeutics Market Cap Historical Data

The historical data trend for Jasper Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jasper Therapeutics Market Cap Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Market Cap
- 297.16 18.37 88.08

Jasper Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 198.06 151.80 77.60 88.08 442.91

Competitive Comparison of Jasper Therapeutics's Market Cap

For the Biotechnology subindustry, Jasper Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jasper Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's Market Cap falls into.



Jasper Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Jasper Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$7.89*11.1639
=$88.08

Jasper Therapeutics's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$29.36*15.0856
=$442.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jasper Therapeutics  (NAS:JSPR) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Jasper Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Jasper Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Jasper Therapeutics (Jasper Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2200 Bridge Parkway, Suite No. 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Executives
Thomas G Wiggans director
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jeetinder Singh Mahal officer: Chief Operating Officer C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Ron Martell director, officer: President, CEO & Director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Scott C. Brun director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Edwin Jonathan Tucker officer: Chief Medical Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Anna Louise French director C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Kurt Von Emster director, 10 percent owner 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Gary E Rieschel 10 percent owner
Qiming U.s. Healthcare Fund Ii, L.p. 10 percent owner 350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Mark Mcdade 10 percent owner C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Qiming U.s. Healthcare Gp Ii, Llc 10 percent owner 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004

Jasper Therapeutics (Jasper Therapeutics) Headlines

From GuruFocus